Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
CN NMPA Enacts New Rules to Tighten Oversight of Contract Drug Manufacturing
Recommend 54 Positive 100 Negative 21 |
||||
|
||||
|
China's National Medical Products Administration (NMPA) has announced new measures to strengthen oversight of contract drug manufacturing, urging marketing authorization holders and contract manufacturing enterprises to jointly fulfill their primary responsibility for drug quality and safety. The announcement outlines three main areas: reinforcing the responsibilities of contract manufacturing enterprises, enhancing contract manufacturing supervision, and other related matters. Among them, it specifies the general requirements and conditions that contract manufacturing enterprises must meet, emphasizing that before accepting a contract, these enterprises should evaluate the holder and the contracted product. AAStocks Financial News |
||||
Copied to Clipboard
 |
||||
